Eli Lilly and Co
LSE:0Q1G
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Eli Lilly and Co
LSE:0Q1G
|
US |
|
A
|
Alphabet Inc
XHAM:ABEA
|
US |
|
C
|
Commonwealth Bank of Australia
XMUN:CWW
|
AU |
Intrinsic Value
The intrinsic value of 
Eli Lilly and Co (0Q1G) under the Base Case is 222.2038 CHF per share.
Compared with the current market price of 244.9569 CHF, the stock appears
Overvalued by 9% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Eli Lilly and Does
Eli Lilly is a pharmaceutical company that discovers, develops, makes, and sells prescription medicines. Its products treat major disease areas such as diabetes, obesity, cancer, immune disorders, and neurological conditions. The company does not sell consumer goods; it sells regulated drugs that patients get through doctors, pharmacies, hospitals, and health plans.
- Headquarters
- United States of America US
- Employees
- 50 000
- IPO date
- Jul 9, 1970
Revenue & Expenses Breakdown
Eli Lilly and Co
Earnings Waterfall
Eli Lilly and Co
The intrinsic value for Eli Lilly and Co (0Q1G) under the Base Case is 222.2038 CHF.
Compared with the current market price of 244.9569 CHF, the stock appears Overvalued by 9% .